Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis"

Mohamed Attauabi; Jakob Benedict Seidelin; Johan Burisch

doi:10.1016/j.dld.2022.11.009

Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis"

Mohamed Attauabi^*, Jakob Benedict Seidelin, Johan Burisch

^*Corresponding author af dette arbejde

Originalsprog	Engelsk
Tidsskrift	Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Vol/bind	55
Udgave nummer	2
Sider (fra-til)	300-301
Antal sider	2
ISSN	1590-8658
DOI	https://doi.org/10.1016/j.dld.2022.11.009
Status	Udgivet - feb. 2023

Adgang til dokumentet

10.1016/j.dld.2022.11.009

Andre filer og links

Link to publication in Scopus

Citationsformater

Attauabi, M., Seidelin, J. B., & Burisch, J. (2023). Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis". Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 55(2), 300-301. https://doi.org/10.1016/j.dld.2022.11.009

Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis". / Attauabi, Mohamed ; Seidelin, Jakob Benedict ; Burisch, Johan.
I: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Bind 55, Nr. 2, 02.2023, s. 300-301.

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

Attauabi, M , Seidelin, JB & Burisch, J 2023, 'Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis"', Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, bind 55, nr. 2, s. 300-301. https://doi.org/10.1016/j.dld.2022.11.009

Attauabi M , Seidelin JB , Burisch J. Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis". Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2023 feb.;55(2):300-301. Epub 2022 dec. 1. doi: 10.1016/j.dld.2022.11.009

Attauabi, Mohamed ; Seidelin, Jakob Benedict ; Burisch, Johan. / Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis". I: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2023 ; Bind 55, Nr. 2. s. 300-301.

@article{bc2cf03492644f8e8480dd161795d696,

title = "Reply to comment on: {"}Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis{"}",

keywords = "Antibodies, Monoclonal, Humanized/therapeutic use, Biological Therapy, Colitis, Ulcerative/drug therapy, Crohn Disease/drug therapy, Gastrointestinal Agents/therapeutic use, Humans",

author = "Mohamed Attauabi and Seidelin, {Jakob Benedict} and Johan Burisch",

year = "2023",

month = feb,

doi = "10.1016/j.dld.2022.11.009",

language = "English",

volume = "55",

pages = "300--301",

journal = "Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver",

issn = "1590-8658",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis"

AU - Attauabi, Mohamed

AU - Seidelin, Jakob Benedict

AU - Burisch, Johan

PY - 2023/2

Y1 - 2023/2

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Biological Therapy

KW - Colitis, Ulcerative/drug therapy

KW - Crohn Disease/drug therapy

KW - Gastrointestinal Agents/therapeutic use

KW - Humans

UR - http://www.scopus.com/inward/record.url?scp=85146318976&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2022.11.009

DO - 10.1016/j.dld.2022.11.009

M3 - Comment/debate

C2 - 36464612

SN - 1590-8658

VL - 55

SP - 300

EP - 301

JO - Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

JF - Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

IS - 2

ER -